APP and its intracellular domain modulate Alzheimers disease risk gene networks in transgenic APPsw and PSEN1M146I porcine models
Habekost, M.; Poulsen, E.; Enghild, J. J.; Denham, M.; Joergensen, A. L.; Qvist, P.
Show abstract
Alzheimers disease (AD) is a progressive neurodegenerative disorder and the most frequent cause of dementia. The disease has a substantial genetic component comprising both highly penetrant familial mutations (APP, PSEN1, and PSEN2) and sporadic cases with complex genetic etiology. Mutations in APP and PSEN1/2 alter the proteolytic processing of APP to its metabolites, including A{beta} and APP Intracellular Domain (AICD). In this study, we use transgenic porcine models carrying the human APPsw and PSEN1M146I transgenes to demonstrate the pathobiological relevance of transcriptional regulation facilitated by APP and its AICD domain. Through molecular characterization of hippocampal tissue, we describe the differential expression of gene sets that cluster in molecular pathways with translational relevance to AD. We further identify phosphorylated and unphosphorylated AICD in differential complexes with proteins implicated in signal transduction and transcriptional regulation. Integrative genomic analysis of transcriptional changes in somatic cell cultures derived from pigs treated with {gamma}-secretase inhibitor demonstrates the importance of {gamma}-secretase APP processing in transcriptional regulation. Our data supports a model in which APP and, in particular, its AICD domain, modulates gene networks associated with AD pathobiology through interaction with signaling proteins. One Sentence SummaryUtilizing transgenic porcine models, our study reveals that Alzheimers disease-related mutations affect neuronal gene expression and highlights the role of the AICD domain of APP in modulating gene networks associated with Alzheimers pathobiology.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Diabetic phenotype in mouse and humans with β-amyloid pathology reduces the number of microglia around β-amyloid plaques 95%
- Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer’s disease 95%
- APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology 95%
Similar papers in this journal
Similar papers in this journal
- Chronic optogenetic activation of hippocampal pyramidal neurons replicates the proteome footprint of Alzheimer's disease-like pathology 95%
- Dimeric Transmembrane Orientations of APP/C99 Regulate γ-Secretase Processing Line Impacting Signaling and Oligomerization 94%
- Cross-species comparative hippocampal transcriptomics in Alzheimer's disease 94%